Forums
New posts
Forum list
Search forums
What's new
New posts
New resources
Latest activity
Trending Threads
Resources
Latest reviews
Search resources
FarmTV
Farm Compare
Search
Tokens/Searches
Calendar
Upcoming Events
Members
Registered members
Current visitors
New Resources
New posts
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Forum list
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Farm Business
Agricultural Matters
Ivermectin , covid cure
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="ollie989898" data-source="post: 7878710" data-attributes="member: 54866"><p>TOGETHER trial starting to churn out results now. Hydroxychloroquine findings published. Others in the pipeline for publishing and release.</p><p></p><p>[URL unfurl="true"]https://www.togethertrial.com/trial-specifications[/URL]</p><p></p><p></p><p></p><p>[ATTACH=full]1002322[/ATTACH]</p><p></p><p></p><p>Some details of the trials in question:</p><p></p><p><strong><em>Clinical trials</em></strong></p><p><em></em></p><p><em>As of the most recent update, the TOGETHER Trial has concluded investigations on five medications (hydroxychloroquine, lopinavir / ritonavir, ivermectin, fluvoxamine maleate, and metformin), and two investigations (doxazosin and Peginterferon Lambda) are continuing (see Table 1). A summary of the progression of clinical trials is presented in Figure 1.</em></p><p><em></em></p><p><em>Recruitment for the Trial began in 2020 and has been ongoing to present day. Eligible patients are randomized with equal chance to an investigational product (IP) or to placebo. Patients are included if they are:</em></p><p><em></em></p><ul> <li data-xf-list-type="ul"><em>18 years of age</em></li> <li data-xf-list-type="ul"><em>have a positive antigen test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)</em></li> <li data-xf-list-type="ul"><em>have an indication for high risk of disease severity, including co-morbidities, older age, or high body mass index.</em></li> </ul><p></p><p></p><p>Write up of the trial in JAMA is below. High power study, randomised clinical trial. About 600 patients in three treatment arms (nicely reaching the 200 needed to be statistically worthwhile). The lopinavir-ritonavir treatment was interesting because of the background of these drugs showing demonstrable activity in vitro but also in MERS in non-human primate models:</p><p></p><p><em>...Lopinavir-ritonavir, an HIV aspartate protease inhibitor type 1, has been reported to have <span style="color: rgb(184, 49, 47)">in vitro inhibitory activity against SARS-CoV</span>,<a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2779044#zoi210214r9" target="_blank">9</a> and<span style="color: rgb(184, 49, 47)"> also improved clinical, radiological, and pathological outcomes in a marmoset model of Middle East respiratory syndrome coronavirus infection</span>....</em></p><p></p><p></p><p>Here is the JAMA link:</p><p></p><p>[URL unfurl="true"]https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2779044[/URL]</p><p></p><p><strong><em>Importance</em></strong><em> Data on the efficacy of hydroxychloroquine or lopinavir-ritonavir for the treatment of high-risk outpatients with COVID-19 in developing countries are needed.</em></p><p><em></em></p><p><em><strong>Objective</strong> To determine whether hydroxychloroquine or lopinavir-ritonavir reduces hospitalization among high-risk patients with early symptomatic COVID-19 in an outpatient setting.</em></p><p><em></em></p><p><em><strong>Design, Setting, and Participants</strong> This randomized clinical trial was conducted in Brazil. Recently symptomatic adults diagnosed with respiratory symptoms from SARS-CoV-2 infection were enrolled between June 2 and September 30, 2020. The planned sample size was 1476 patients, with interim analyses planned after 500 patients were enrolled. The trial was stopped after the interim analysis for futility with a sample size of 685 patients. Statistical analysis was performed in December 2020.</em></p><p><em></em></p><p><em><strong>Interventions</strong> Patients were randomly assigned to hydroxychloroquine (800 mg loading dose, then 400 mg daily for 9 days), lopinavir-ritonavir (loading dose of 800 mg and 200 mg, respectively, every 12 hours followed by 400 mg and 100 mg, respectively, every 12 hours for the next 9 days), or placebo.</em></p><p><em></em></p><p><em><strong>Main Outcomes and Measures</strong> The primary outcomes were COVID-19–associated hospitalization and death assessed at 90 days after randomization. COVID-19–associated hospitalization was analyzed with a Cox proportional hazards model. The trial included the following secondary outcomes: all-cause hospitalization, viral clearance, symptom resolution, and adverse events.</em></p><p><em></em></p><p><em><strong>Results</strong> Of 685 participants, 632 (92.3%) self-identified as mixed-race, 377 (55.0%) were women, and the median (range) age was 53 (18-94) years. A total of 214 participants were randomized to hydroxychloroquine; 244, lopinavir-ritonavir; and 227, placebo. At first interim analysis, the data safety monitoring board recommended stopping enrollment of both hydroxychloroquine and lopinavir-ritonavir groups because of futility. The proportion of patients hospitalized for COVID-19 was 3.7% (8 participants) in the hydroxychloroquine group, 5.7% (14 participants) in the lopinavir-ritonavir group, and 4.8% (11 participants) in the placebo group. We found no significant differences between interventions for COVID-19–associated hospitalization (hydroxychloroquine: hazard ratio<hr /><p>, 0.76 [95% CI, 0.30-1.88]; lopinavir-ritonavir: HR, 1.16 [95% CI, 0.53-2.56] as well as for the secondary outcome of viral clearance through day 14 (hydroxychloroquine: odds ratio [OR], 0.91 [95% CI, 0.82-1.02]; lopinavir-ritonavir: OR, 1.04 [95% CI, 0.94-1.16]). At the end of the trial, there were 3 fatalities recorded, 1 in the placebo group and 2 in the lopinavir-ritonavir intervention group.</em></p><p><em></em></p><p><em><strong>Conclusions and Relevance</strong> In this randomized clinical trial, neither hydroxychloroquine nor lopinavir-ritonavir showed any significant benefit for decreasing COVID-19–associated hospitalization or other secondary clinical outcomes. This trial suggests that expedient clinical trials can be implemented in low-income settings even during the COVID-19 pandemic.</em><hr /></blockquote><p></p>
[QUOTE="ollie989898, post: 7878710, member: 54866"] TOGETHER trial starting to churn out results now. Hydroxychloroquine findings published. Others in the pipeline for publishing and release. [URL unfurl="true"]https://www.togethertrial.com/trial-specifications[/URL] [ATTACH type="full" width="665px"]1002322[/ATTACH] Some details of the trials in question: [B][I]Clinical trials[/I][/B] [I] As of the most recent update, the TOGETHER Trial has concluded investigations on five medications (hydroxychloroquine, lopinavir / ritonavir, ivermectin, fluvoxamine maleate, and metformin), and two investigations (doxazosin and Peginterferon Lambda) are continuing (see Table 1). A summary of the progression of clinical trials is presented in Figure 1. Recruitment for the Trial began in 2020 and has been ongoing to present day. Eligible patients are randomized with equal chance to an investigational product (IP) or to placebo. Patients are included if they are: [/I] [LIST] [*][I]18 years of age[/I] [*][I]have a positive antigen test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)[/I] [*][I]have an indication for high risk of disease severity, including co-morbidities, older age, or high body mass index.[/I] [/LIST] Write up of the trial in JAMA is below. High power study, randomised clinical trial. About 600 patients in three treatment arms (nicely reaching the 200 needed to be statistically worthwhile). The lopinavir-ritonavir treatment was interesting because of the background of these drugs showing demonstrable activity in vitro but also in MERS in non-human primate models: [I]...Lopinavir-ritonavir, an HIV aspartate protease inhibitor type 1, has been reported to have [COLOR=rgb(184, 49, 47)]in vitro inhibitory activity against SARS-CoV[/COLOR],[URL='https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2779044#zoi210214r9']9[/URL] and[COLOR=rgb(184, 49, 47)] also improved clinical, radiological, and pathological outcomes in a marmoset model of Middle East respiratory syndrome coronavirus infection[/COLOR]....[/I] Here is the JAMA link: [URL unfurl="true"]https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2779044[/URL] [B][I]Importance[/I][/B][I] Data on the efficacy of hydroxychloroquine or lopinavir-ritonavir for the treatment of high-risk outpatients with COVID-19 in developing countries are needed. [B]Objective[/B] To determine whether hydroxychloroquine or lopinavir-ritonavir reduces hospitalization among high-risk patients with early symptomatic COVID-19 in an outpatient setting. [B]Design, Setting, and Participants[/B] This randomized clinical trial was conducted in Brazil. Recently symptomatic adults diagnosed with respiratory symptoms from SARS-CoV-2 infection were enrolled between June 2 and September 30, 2020. The planned sample size was 1476 patients, with interim analyses planned after 500 patients were enrolled. The trial was stopped after the interim analysis for futility with a sample size of 685 patients. Statistical analysis was performed in December 2020. [B]Interventions[/B] Patients were randomly assigned to hydroxychloroquine (800 mg loading dose, then 400 mg daily for 9 days), lopinavir-ritonavir (loading dose of 800 mg and 200 mg, respectively, every 12 hours followed by 400 mg and 100 mg, respectively, every 12 hours for the next 9 days), or placebo. [B]Main Outcomes and Measures[/B] The primary outcomes were COVID-19–associated hospitalization and death assessed at 90 days after randomization. COVID-19–associated hospitalization was analyzed with a Cox proportional hazards model. The trial included the following secondary outcomes: all-cause hospitalization, viral clearance, symptom resolution, and adverse events. [B]Results[/B] Of 685 participants, 632 (92.3%) self-identified as mixed-race, 377 (55.0%) were women, and the median (range) age was 53 (18-94) years. A total of 214 participants were randomized to hydroxychloroquine; 244, lopinavir-ritonavir; and 227, placebo. At first interim analysis, the data safety monitoring board recommended stopping enrollment of both hydroxychloroquine and lopinavir-ritonavir groups because of futility. The proportion of patients hospitalized for COVID-19 was 3.7% (8 participants) in the hydroxychloroquine group, 5.7% (14 participants) in the lopinavir-ritonavir group, and 4.8% (11 participants) in the placebo group. We found no significant differences between interventions for COVID-19–associated hospitalization (hydroxychloroquine: hazard ratio [HR], 0.76 [95% CI, 0.30-1.88]; lopinavir-ritonavir: HR, 1.16 [95% CI, 0.53-2.56] as well as for the secondary outcome of viral clearance through day 14 (hydroxychloroquine: odds ratio [OR], 0.91 [95% CI, 0.82-1.02]; lopinavir-ritonavir: OR, 1.04 [95% CI, 0.94-1.16]). At the end of the trial, there were 3 fatalities recorded, 1 in the placebo group and 2 in the lopinavir-ritonavir intervention group. [B]Conclusions and Relevance[/B] In this randomized clinical trial, neither hydroxychloroquine nor lopinavir-ritonavir showed any significant benefit for decreasing COVID-19–associated hospitalization or other secondary clinical outcomes. This trial suggests that expedient clinical trials can be implemented in low-income settings even during the COVID-19 pandemic.[/HR][/I][HR][/hr] [/QUOTE]
Insert quotes…
Verification
Post reply
Forums
Farm Business
Agricultural Matters
Ivermectin , covid cure
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top